IQVIA HOLDINGS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 229.6 USD | +1.11% |
|
-0.68% | -0.77% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- One of the major weak points of the company is its financial situation.
- With an expected P/E ratio at 31.31 and 26.29 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 3.47 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -0.77% | 41.83B | B | ||
| +67.53% | 63.85B | B- | ||
| +45.66% | 40.65B | A | ||
| -10.72% | 27.12B | C | ||
| +13.30% | 26.52B | B- | ||
| -22.79% | 18.69B | B | ||
| +4.70% | 12.73B | B+ | ||
| +24.10% | 12.11B | B+ | ||
| +27.41% | 12.07B | C+ | ||
| -8.12% | 11.19B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- IQV Stock
- Ratings Iqvia Holdings Inc.
